Monopar Therapeutics (NASDAQ:MNPR) Stock Rating Upgraded by Jonestrading

Monopar Therapeutics (NASDAQ:MNPR) was upgraded by equities researchers at Jonestrading from a “hold” rating to a “buy” rating in a report issued on Thursday, Benzinga reports. The brokerage currently has a $2.00 price objective on the stock. Jonestrading’s price target suggests a potential upside of 156.08% from the stock’s current price.

Monopar Therapeutics Trading Up 1.4 %

Monopar Therapeutics stock opened at $0.78 on Thursday. The stock has a market cap of $13.63 million, a P/E ratio of -1.28 and a beta of 1.19. The stock has a 50 day moving average of $0.70 and a 200-day moving average of $0.51. Monopar Therapeutics has a 52 week low of $0.27 and a 52 week high of $1.75.

Hedge Funds Weigh In On Monopar Therapeutics

A hedge fund recently bought a new stake in Monopar Therapeutics stock. Windsor Advisory Group LLC acquired a new position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 89,974 shares of the company’s stock, valued at approximately $56,000. Windsor Advisory Group LLC owned about 0.64% of Monopar Therapeutics at the end of the most recent reporting period. Institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.